Clasificación molecular del cáncer de mama y su correlación clínica

objective: the molecular classification have defined risk groups and different treatments, the present study explores how these groups were related. method: 320 patients examinee between january 2007 and july 2009 all patients in which we identify breast cancer in our institution is conducting an assessment of immunohistochemistry according to these results are classified in four subtypes: luminal a and b, her2nneu and basal like, also evaluating clinical-pathologic characteristic: diagnostic method, age, clinical presentation, tumor size, degree of differentiation, initial treatment. results: in 320 patients the most frequent tumor was luminal a with a 60.63 %, followed by basal like (28.75 %) her2 neu (9.06 %) luminal b (1.56 %). in relation with worst prognosis of tumors were found more palpable tumors and less subclinical diagnostic by imaging, higher frequency in groups of younger women with larger tumors to physical examination and more undifferentiated. tumors taking all these considerations needed to initiate treatment of induction chemotherapy as first therapeutic modality in 60.68 % of the basal and like a her2neu of 62.06 %, higher than 52.57 % of the tumors more frequent luminal a. conclusions: the molecular classification of breast cancer let us identified tumors with worst prognosis. the histological features of the tumor have also identified risk groups, but with very broad therapeutic connotations, especially because it allows selection of treatments. on the other hand is only the molecular classification that determines the possibility to provide patients, selective chemotherapy treatments.